SCHEMBL21297237

SCHEMBL21297237

Fc1cc(S)cc(NC2CCOCC2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 4/20 0.42
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
MAPK14 Q16539 5/20 0.34
BACE1 P56817 1/20 0.34
BACE2 Q9Y5Z0 1/20 0.34
CTSV O60911 1/20 0.33
PLAT P00750 1/20 0.33
CTSL P07711 1/20 0.33
CTSB P07858 1/20 0.33
CTSH P09668 1/20 0.33
CTSS P25774 1/20 0.33
CASP14 P31944 1/20 0.33
CTSK P43235 1/20 0.33
CASP4 P49662 1/20 0.33
CASP5 P51878 1/20 0.33
CASP6 P55212 1/20 0.33
CTSZ Q9UBR2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15830063 0.80 MAPK1 (0.46) MAPK1MAPK14BACE1BACE2KDM4E
SCHEMBL21464826 0.80 MAPK1 (0.39) MAPK1MAPK14BACE1BACE2KDM4E
SCHEMBL21064114 0.76 CSNK1D (0.38) MAPK1MAPK14BACE1BACE2KDM4E
SCHEMBL16217357 0.76 MAPK1 (0.36) MAPK1MAPK14BACE1BACE2KDM4E
SCHEMBL1343010 0.75 MAPK1 (0.43) MAPK1HDAC3HDAC1HDAC2HDAC6
SCHEMBL488077 0.73 MAPK1 (0.44) MAPK1MAPK14BACE1BACE2MAPK8
SCHEMBL21297220 0.72 MAPK1 (0.45) MAPK1BACE1BACE2GAKOPRL1
SCHEMBL10291039 0.69 MAPK1 (0.53) MAPK1HDAC3HDAC1HDAC2HDAC6
SCHEMBL30040202 0.69 BACE1 (0.43) MAPK1HDAC3HDAC1HDAC2BACE1
SCHEMBL23576766 0.66 KDM4E (0.37) CTSVPLATCTSLCTSBCTSH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10391089-B2 PRMT5 inhibitors and uses therof Epizyme, Inc. (US) 2019-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10391089-B2 PRMT5 inhibitors and uses therof PRMT5, PRMT1, PRMT6 MAPK1 2668/4885HDAC3 183/4885HDAC1 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.